New sickle cell drug trial halted early
NCT ID NCT05660265
First seen Jan 23, 2026 · Last updated May 11, 2026 · Updated 19 times
Summary
This early-stage study tested a single dose of an experimental drug called GSK4172239D in 11 adults with sickle cell disease. The goal was to check safety and how the drug moves through the body. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Miami, Florida, 33155, United States
-
GSK Investigational Site
Tamarac, Florida, 33321, United States
-
GSK Investigational Site
Atlanta, Georgia, 30315, United States
-
GSK Investigational Site
Columbus, Georgia, 31904, United States
-
GSK Investigational Site
Riverdale, Georgia, 30274, United States
-
GSK Investigational Site
Las Vegas, Nevada, 89113, United States
Conditions
Explore the condition pages connected to this study.